Watch for FDA feedback on EB613 Phase 3 protocol, expected imminently after late-April target. A positive response would be a significant catalyst. The BVF investment signals institutional confidence but introduces dilution via warrants.
Price Chart
Executive Summary
Entera Bio reported Q1 2026 net loss of $3.5M ($-0.07/share), beating the $-0.08 consensus by 12.5%. The pre-revenue biotech progressed its lead osteoporosis candidate EB613 toward Phase 3, submitted a streamlined protocol to the FDA, and secured a $8.5M private placement from BVF Partners, extending cash runway through Q1 2027.
Key Financial Metrics
Key Facts
- Net loss for Q1 2026: $3.5M vs $2.6M in Q1 2025
- EPS: $-0.07 (beat consensus of $-0.08 by 12.5%)
- Cash and equivalents: $4.1M at quarter-end; $20.4M post private placement
- Phase 3 protocol for EB613 (oral osteoporosis treatment) submitted to FDA
- BVF Partners led a private placement to fund EB613 pivotal study
- R&D expenses doubled to $2.3M vs $1.1M year-over-year
Financial Impact
Net loss increased 35% YoY to $3.5M, but cash runway extended through Q1 2027 via $8.5M private placement
Risk Factors
- Clinical trial failure or regulatory setbacks for EB613
- Need for additional capital beyond Q1 2027
- Dilution from BVF private placement warrants
- No revenue stream to offset operating losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178913-26-002455 |
| Document: zk2635218.htm | 0001178913-26-002455 |
| Document: 0001178913-26-002455-index-headers.html | 0001178913-26-002455 |
| Document: 0001178913-26-002455-index.html | 0001178913-26-002455 |
| Document: 0001178913-26-002455.txt | 0001178913-26-002455 |
| 8-K Data (Synthetic) | 0001178913-26-002455 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | DEF 14A | $2.77 | awaiting T+60 | — | $2.92 (+5.42%) |
Oct 6, 2026 20d ago | 8-K | $2.53 | awaiting T+60 | — | $2.92 (+15.42%) |
Aug 27, 2026 8w ago | Press Release | $3.08 | awaiting T+60 | — | $2.92 (−5.19%) |
Aug 18, 2026 9w ago | 8-K | $2.89 | awaiting T+60 | — | $2.92 (+1.04%) |
Aug 7, 2026 11w ago | Press Release | $3.04 | awaiting T+60 | — | $2.92 (−3.95%) |
Jul 29, 2026 12w ago | Press Release | $3.00 $3.02 | ▲ +0.67% | ▼ −4.06% | $2.92 (−2.67%) |
Jun 16, 2026 18w ago | Press Release | $1.18 $2.79 | ▲ +136.44% | ▲ +135.44% | $2.92 (+147.46%) |
May 28, 2026 21w ago | Press Release | $1.22 $3.23 | ▲ +164.75% | ▲ +163.02% | $2.92 (+139.34%) |
May 18, 2026 23w ago | EFFECT | $1.23 $2.80 | ▲ +127.64% | ▲ +122.79% | $2.92 (+137.40%) |
May 8, 2026 24w ago | S-3 | $1.17 $2.81 | ▲ +140.17% | ▲ +135.78% | $2.92 (+149.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers